Oncternal Therapeutics, Inc. (ONCT): Price and Financial Metrics


Oncternal Therapeutics, Inc. (ONCT)

Today's Latest Price: $2.64 USD

0.28 (-9.59%)

Updated Dec 2 4:00pm

Add ONCT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

ONCT Stock Summary

  • The ratio of debt to operating expenses for Oncternal Therapeutics Inc is higher than it is for about just 5.62% of US stocks.
  • With a price/sales ratio of 25.87, Oncternal Therapeutics Inc has a higher such ratio than 92.83% of stocks in our set.
  • As for revenue growth, note that ONCT's revenue has grown 107.06% over the past 12 months; that beats the revenue growth of 94.83% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Oncternal Therapeutics Inc, a group of peers worth examining would be SNSS, QUIK, AVEO, AKBA, and SILC.
  • Visit ONCT's SEC page to see the company's official filings. To visit the company's web site, go to www.oncternal.com.

ONCT Stock Price Chart Interactive Chart >

Price chart for ONCT

ONCT Price/Volume Stats

Current price $2.64 52-week high $6.28
Prev. close $2.92 52-week low $1.49
Day low $2.60 Volume 1,398,926
Day high $2.82 Avg. volume 739,912
50-day MA $2.43 Dividend yield N/A
200-day MA $2.72 Market Cap 59.00M

Oncternal Therapeutics, Inc. (ONCT) Company Bio


Oncternal Therapeutics (formerly GTx, Inc.), a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company was founded in 1997 and is based in Memphis, Tennessee.


ONCT Latest News Stream


Event/Time News Detail
Loading, please wait...

ONCT Latest Social Stream


Loading social stream, please wait...

View Full ONCT Social Stream

Latest ONCT News From Around the Web

Below are the latest news stories about Oncternal Therapeutics Inc that investors may wish to consider to help them evaluate ONCT as an investment opportunity.

Oncternal presents TK216 interim data from early stage study in Ewing sarcoma

Oncternal Therapeutics ([[ONCT]] -4.1%) has announced the presentation of interim clinical data from its ongoing Phase 1 trial for TK216, in patients with relapsed or refractory Ewing sarcoma, tumor that forms in bone or soft tissue. Data were presented at European Society for Medical Oncology congress.This study is evaluating safety, tolerability, pharmacokinetics, and tumor...

Seeking Alpha | September 21, 2020

Oncternal Therapeutics raises "bought deal" offering to $4.5M

Due to demand, Oncternal Therapeutics' (ONCT) book runner H.C. Wainwright & Co. has agreed to increase the size of its previous offering to purchase ~2.14M shares of common stock (from 1.67M) at $2.10/share, for expected gross proceeds of ~$4.5M. Underwriter's over-allotment is an additional 321,428 shares.Closing date is September 1.Yesterday's...

Seeking Alpha | August 28, 2020

Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2020 financial results after U.S. financial markets close on Thursday, August 6, 2020. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the Company’s financial results and provide a comprehensive business update.

Yahoo | July 30, 2020

Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agreements with existing institutional investors and other accredited investors, for the purchase and sale of 2,581,867 shares of its common stock, at a purchase price of $2.3825 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Oncternal also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 1,290,933 shares of its common stock. The closing of the offering is expected to occur on or about July 21, 2020, subject to the satisfaction of customary closing conditions.

Yahoo | July 20, 2020

Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designations of cirmtuzumab for treatment of mantle cell lymphoma (MCL) and for treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Cirmtuzumab is an investigational anti-ROR1 monoclonal antibody being evaluated in clinical trials in patients with MCL, CLL and HER2-negative breast cancer.

Yahoo | June 30, 2020

Read More 'ONCT' Stories Here

ONCT Price Returns

1-mo 67.09%
3-mo 26.32%
6-mo -11.71%
1-year -48.84%
3-year -97.10%
5-year -95.94%
YTD -33.16%
2019 -27.66%
2018 -93.86%
2017 140.72%
2016 -24.57%
2015 -4.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9445 seconds.